EU Approves First-Ever CETP Inhibitor: NewAmsterdam and Menarini's Obicetrapib Cleared as Ubeslo and Evlarco
- The European Commission approved obicetrapib, an oral once-daily CETP (cholesteryl ester transfer protein) inhibitor, marking the first-ever regulatory approval anywhere in the world for this drug class.
- Two products were cleared for hypercholesterolemia, including heterozygous familial and mixed dyslipidemia: monotherapy Ubeslo and a fixed-dose combination with ezetimibe, Evlarco.
- Approval rests on three NewAmsterdam Pharma trials showing LDL cholesterol reductions of up to roughly 40% with monotherapy and about 50% with the combination versus placebo.
- Menarini Group holds exclusive commercialization rights across Europe under its licensing agreement with NewAmsterdam, which stands to receive tiered royalties and milestone payments.
💡 Points
CETP inhibitors were pharma's most notorious graveyard — torcetrapib killed patients, evacetrapib and anacetrapib flamed out on efficacy — so obicetrapib's clearance is a rare mechanism resurrection, not just another lipid drug. The Menarini licensing deal also shows how a small biotech de-risks European commercialization: NewAmsterdam banks royalties and milestones while Menarini fronts sales infrastructure against entrenched PCSK9 and statin-ezetimibe incumbents.